(919) 237-4897 info@t3dtherapeutics.com

John Ratliff recently retired from Quintiles as President and Chief Operating Officer. He led Quintiles’ Global Services organization with it’s clinical research, commercial, consulting, lab operations and was a member of the company’s Board of Directors. John helped lead the $1B 2013 IPO for the company as it grew from a company of $1B in revenues when it was taken private in late 2003 (John joined in June of 2004) to the $4B Fortune 500 public company that it is today.

Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 32,000 employees conducting business in approximately 100 countries, Quintiles helped develop or commercialize all of 2013’s top-100 best-selling drugs on the market. Quintiles applies the breadth and depth of it’s service offerings along with extensive therapeutic, scientific and analytics expertise to help customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes.

Prior to joining Quintiles, Ratliff worked for Acterna, the world’s second largest provider of communications test solutions for telecommunications and cable network operators. Before moving to Acterna in 2000, he worked 19 years at IBM, holding several positions of increasing responsibility. His latter positions at IBM included Vice President for Finance and Planning, Latin America, Vice President for Finance and Planning, PC Company, and Assistant Controller.
John received his bachelor’s degree in industrial and systems engineering from the Georgia Institute of Technology in Atlanta and his MBA from Duke University in Durham, North Carolina.